Although cancer cells can be identified and eliminated by the immune system, human cancers often co-opt different nodes of the cancer immunity cycle (Figure 1) to evade immune surveillance. Immuno-Oncology (IO) has revolutionized our ability to treat cancer by providing therapies that enhance the immune system’s ability to recognize cancer cells, overcome cancer-driven immunosuppressive barriers and eliminate cancer cells.

At IDEAYA, our IO portfolio is designed to overcome the genetic and environmental factors in the tumor microenvironment (TME) that drive cancer cell evasion from both innate and adaptive immune cells. While several mechanisms play a role in immune evasion, we are focused on inhibition of metabolite-driven suppression of lymphoid and myeloid cells via the Aryl Hydrocarbon Receptor.

Cancer-immunity cycle (Figure 1)